Protagonist Therapeutics Inc (PTGX)
41.65
+1.00
(+2.46%)
USD |
NASDAQ |
Nov 21, 16:00
41.69
+0.04
(+0.10%)
After-Hours: 20:00
Protagonist Therapeutics Enterprise Value: 2.014B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.014B |
| November 20, 2024 | 1.954B |
| November 19, 2024 | 1.835B |
| November 18, 2024 | 1.938B |
| November 15, 2024 | 1.981B |
| November 14, 2024 | 1.977B |
| November 13, 2024 | 2.074B |
| November 12, 2024 | 2.104B |
| November 11, 2024 | 2.303B |
| November 08, 2024 | 2.286B |
| November 07, 2024 | 2.369B |
| November 06, 2024 | 2.368B |
| November 05, 2024 | 2.267B |
| November 04, 2024 | 2.318B |
| November 01, 2024 | 2.318B |
| October 31, 2024 | 2.263B |
| October 30, 2024 | 2.366B |
| October 29, 2024 | 2.414B |
| October 28, 2024 | 2.400B |
| October 25, 2024 | 2.344B |
| October 24, 2024 | 2.326B |
| October 23, 2024 | 2.304B |
| October 22, 2024 | 2.295B |
| October 21, 2024 | 2.267B |
| October 18, 2024 | 2.327B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.330B |
| October 16, 2024 | 2.328B |
| October 15, 2024 | 2.367B |
| October 14, 2024 | 2.290B |
| October 11, 2024 | 2.215B |
| October 10, 2024 | 2.126B |
| October 09, 2024 | 2.161B |
| October 08, 2024 | 2.148B |
| October 07, 2024 | 2.138B |
| October 04, 2024 | 2.172B |
| October 03, 2024 | 2.170B |
| October 02, 2024 | 2.209B |
| October 01, 2024 | 2.172B |
| September 30, 2024 | 2.210B |
| September 27, 2024 | 2.061B |
| September 26, 2024 | 2.083B |
| September 25, 2024 | 2.154B |
| September 24, 2024 | 2.180B |
| September 23, 2024 | 2.154B |
| September 20, 2024 | 2.224B |
| September 19, 2024 | 2.141B |
| September 18, 2024 | 2.073B |
| September 17, 2024 | 2.081B |
| September 16, 2024 | 2.157B |
| September 13, 2024 | 2.206B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-10.09M
Minimum
Dec 03 2019
2.414B
Maximum
Oct 29 2024
857.13M
Average
805.70M
Median
Mar 30 2021
Enterprise Value Benchmarks
| Johnson & Johnson | 389.84B |
| Assembly Biosciences Inc | -1.389M |
| Precision BioSciences Inc | -29.06M |
| Entrada Therapeutics Inc | 226.09M |
| NovaBay Pharmaceuticals Inc | 2.798M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.21M |
| Revenue (Quarterly) | 4.675M |
| Total Expenses (Quarterly) | 46.13M |
| EPS Diluted (Quarterly) | -0.54 |
| Profit Margin (Quarterly) | -710.4% |
| Earnings Yield | 6.39% |
| Operating Earnings Yield | 5.80% |
| Normalized Earnings Yield | 6.387 |